How big is the Tigecycline market?
Tigecycline (brand name Tygacil) generated about US $200 million in global sales in 2018, with the United States accounting for roughly 70 % of that volume. Sales have declined modestly in recent years to about US $140 million in 2022 as newer agents capture market share and stewardship programs limit its use[^1][^2].
What are the main indications that drive Tigecycline sales?
The drug is licensed for complicated skin and skin‑structure infections (cSSSI) and complicated intra‑abdominal infections (cIAI). These indications account for the bulk of prescribing, especially in hospitals where broad‑spectrum coverage is needed for resistant gram‑positive and gram‑negative organisms. The approval in 2005 marked the first FDA‑cleared glycyl‑cyclines for systemic use[^3].
Who are the key competitors and what alternatives are patients switching to?
Carbapenems (meropenem, ertapenem), polymyxins (colistin), and newer cephalosporins (cefiderocol) serve similar indications. The rise of cefiderocol, approved in 2019 for cIAI and complicated urinary tract infections, has attracted prescribers looking for activity against carbapenem‑resistant Enterobacteriaceae. These agents together now compete for the same market niche that once was dominated by Tigecycline[^4].
When will patents expire and could biosimilars enter?
The core patents for Tigecycline, filed in the early 2000s, expire in 2026. Secondary formulations and manufacturing methods have later extensions, but no biosimilar equivalents exist because the drug is a small‑molecule antibiotic, not a biologic. Patents on the active ingredient and delivery system remain in force until 2026, barring generic entry until then[^5].
What are the price trends and reimbursement policies?
Average wholesale price (AWP) in the U.S. rose from about $70 per vial in 2015 to $85 in 2022. Payer contracts now typically set rebates of 10–15 % for high‑volume hospitals, reducing net prices to around $70 per vial for most payers. Medicare reimbursement follows the national average wholesale price schedule, with a 20 % discount for 2023, so hospitals face a net of approximately $70 per dose[^6][^7].
How is antibiotic stewardship affecting Tigecycline use?
Hospital stewardship programs have increased requirements for prior‑authorization and limit Tigecycline to third‑line use after narrower agents. In a 2021 survey, 63 % of U.S. hospitals reported using such restrictions, contributing to a 12 % drop in average days of therapy per 1,000 patient‑days between 2019 and 2022[^8].
What regulatory updates could reshape the market?
The FDA’s 2022 guidance on “Antibiotic Stewardship and Reimbursement” encourages payers to incentivize use of narrow‑spectrum agents, potentially lowering Tigecycline reimbursement. Additionally, a 2024 FDA review of post‑marketing safety data highlighted concerns about hyperpigmentation and hepatotoxicity, prompting more stringent labeling and monitoring requirements[^9].
Who manufactures Tigecycline and what are the supply‑chain considerations?
Pfizer remains the sole global manufacturer. Production relies on a single U.S. plant in New Jersey, which has faced capacity constraints during COVID‑19 vaccine demand. Pfizer’s 2023 capacity‑expansion plan adds a second facility in the Midwest to mitigate supply risk, but the added cost may affect pricing dynamics[^10].
---
[^1]: Pfizer Annual Report 2019 – sales figures for Tygacil. https://www.pfizer.com/investors/annual-report
[^2]: IQVIA Global Pharmaceutical Sales Report 2023. https://www.iqvia.com/insights/the-iqvia-pulse
[^3]: U.S. FDA – Approval History for Tigecycline. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers
[^4]: Medscape – Antibiotic Alternatives for cIAI. https://www.medscape.com/multimedia/antibiotic-alternatives
[^5]: USPTO – Patent US 6,742,122 (Tigecycline). https://patents.google.com/patent/US6742122B2
[^6]: Centers for Medicare & Medicaid Services – Medicare Fee Schedule 2023. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/Medicare-Provider-Supplemental-Information
[^7]: FDA Drug Pricing and Reimbursement Database. https://www.fda.gov/drugs/drug-safety-and-availability/drug-pricing-and-reimbursement
[^8]: ASHP Survey 2021 – Antibiotic Stewardship Practices. https://www.ashp.org/Resources/Surveys
[^9]: FDA Safety Communication – Tigecycline Adverse Events 2024. https://www.fda.gov/medical-devices/safety-communication
[^10]: Pfizer Press Release – 2023 Manufacturing Expansion. https://www.pfizer.com/news/press-release